

Erica Novo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8419492/publications.pdf>

Version: 2024-02-01

55
papers

4,241
citations

126708

33
h-index

168136

53
g-index

56
all docs

56
docs citations

56
times ranked

6262
citing authors

#	ARTICLE	IF	CITATIONS
1	Redox mechanisms in hepatic chronic wound healing and fibrogenesis. <i>Fibrogenesis and Tissue Repair</i> , 2008, 1, 5.	3.4	328
2	Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. <i>Hepatology</i> , 2005, 42, 1339-1348.	3.6	310
3	Redox mechanisms switch on hypoxia-dependent epithelialâ€mesenchymal transition in cancer cells. <i>Carcinogenesis</i> , 2008, 29, 2267-2278.	1.3	274
4	Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. <i>Gut</i> , 2008, 57, 223-231.	6.1	248
5	Epithelialâ€Mesenchymal Transition: From Molecular Mechanisms, Redox Regulation to Implications in Human Health and Disease. <i>Antioxidants and Redox Signaling</i> , 2010, 12, 1383-1430.	2.5	226
6	The upâ€regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1â€±. <i>Journal of Neurochemistry</i> , 2009, 108, 1045-1056.	2.1	217
7	Proangiogenic Cytokines as Hypoxia-Dependent Factors Stimulating Migration of Human Hepatic Stellate Cells. <i>American Journal of Pathology</i> , 2007, 170, 1942-1953.	1.9	196
8	Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. <i>Journal of Hepatology</i> , 2009, 50, 1102-1111.	1.8	186
9	Cellular and molecular mechanisms in liver fibrogenesis. <i>Archives of Biochemistry and Biophysics</i> , 2014, 548, 20-37.	1.4	177
10	Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. <i>Gut</i> , 2005, 55, 1174-1182.	6.1	143
11	Liver fibrosis: a dynamic and potentially reversible process. <i>Histology and Histopathology</i> , 2010, 25, 1075-91.	0.5	110
12	Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. <i>Journal of Hepatology</i> , 2011, 54, 964-974.	1.8	109
13	Angiogenesis and Fibrogenesis in Chronic Liver Diseases. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 477-488.	2.3	104
14	4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. <i>Journal of Hepatology</i> , 2004, 40, 60-68.	1.8	103
15	Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. <i>Journal of Hepatology</i> , 2007, 46, 230-238.	1.8	93
16	Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. <i>World Journal of Gastroenterology</i> , 2010, 16, 281.	1.4	91
17	Hepatic myofibroblasts: A heterogeneous population of multifunctional cells in liver fibrogenesis. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2089-2093.	1.2	87
18	Curcumin limits the fibrogenic evolution of experimental steatohepatitis. <i>Laboratory Investigation</i> , 2010, 90, 104-115.	1.7	84

#	ARTICLE	IF	CITATIONS
19	Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. <i>Gut</i> , 2006, 55, 90-97.	6.1	78
20	Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. <i>International Journal of Molecular Medicine</i> , 2010, 26, 471-6.	1.8	78
21	ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2700.	1.8	72
22	The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. <i>Journal of Pathology</i> , 2012, 226, 588-597.	2.1	71
23	Hypoxia-inducible factor 2 β drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. <i>Hepatology</i> , 2018, 67, 2196-2214.	3.6	66
24	Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. <i>Clinical Science</i> , 2012, 123, 459-471.	1.8	59
25	Hypoxia up-regulates SERPINB3 through HIF-2 β in human liver cancer cells. <i>Oncotarget</i> , 2015, 6, 2206-2221.	0.8	59
26	Angiogenesis and liver fibrogenesis. <i>Histology and Histopathology</i> , 2009, 24, 1323-41.	0.5	55
27	Dissection of the Biphasic Nature of Hypoxia-Induced Motogenic Action in Bone Marrow-Derived Human Mesenchymal Stem Cells. <i>Stem Cells</i> , 2011, 29, 952-963.	1.4	51
28	Therapeutic pro-fibrogenic signaling pathways in fibroblasts. <i>Advanced Drug Delivery Reviews</i> , 2017, 121, 57-84.	6.6	51
29	The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, S4.	3.4	50
30	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0172575.	1.1	49
31	Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G210-G219.	1.6	39
32	NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X7 signalling. <i>Clinical Science</i> , 2016, 130, 1793-1806.	1.8	39
33	Hypoxia, hypoxia-inducible factors and fibrogenesis in chronic liver diseases. <i>Histology and Histopathology</i> , 2014, 29, 33-44.	0.5	37
34	Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis. <i>Cells</i> , 2021, 10, 1764.	1.8	35
35	Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. <i>Cells</i> , 2020, 9, 28.	1.8	26
36	SerpB3 Promotes Pro-fibrogenic Responses in Activated Hepatic Stellate Cells. <i>Scientific Reports</i> , 2017, 7, 3420.	1.6	23

#	ARTICLE	IF	CITATIONS
37	SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1 \pm and -2 \pm in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets. <i>Cancers</i> , 2019, 11, 1933.	1.7	22
38	Nrf1 gene expression in the liver: A single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. <i>Journal of Hepatology</i> , 2005, 43, 1096-1097.	1.8	21
39	Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G120-G128.	1.6	19
40	Hepatic myofibroblasts and fibrogenic progression of chronic liver diseases. <i>Histology and Histopathology</i> , 2015, 30, 1011-32.	0.5	18
41	β -Catenin triggers nuclear factor κ B-dependent up-regulation of hepatocyte inducible nitric oxide synthase. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1861-1871.	1.2	17
42	n ω -3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. <i>Liver International</i> , 2014, 34, 918-930.	1.9	17
43	Liver fibrogenesis: un update on established and emerging basic concepts. <i>Archives of Biochemistry and Biophysics</i> , 2020, 689, 108445.	1.4	15
44	Role of Chymase in the Development of Liver Cirrhosis and Its Complications: Experimental and Human Data. <i>PLoS ONE</i> , 2016, 11, e0162644.	1.1	14
45	Hepatocyte-Specific Deletion of HIF2 \pm Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 459-482.	2.3	13
46	Oncostatin α is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. <i>Journal of Pathology</i> , 2022, 257, 82-95.	2.1	12
47	4-Hydroxyalkenals as signal molecules modulating proliferative and adaptative cell responses. <i>BioFactors</i> , 2001, 15, 103-106.	2.6	10
48	SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
49	HDL cholesterol protects from liver injury in mice with intestinal specific LXR \pm activation. <i>Liver International</i> , 2020, 40, 3127-3139.	1.9	8
50	Hepatic Myofibroblasts: A Heterogeneous and Redox-Modulated Cell Population in Liver Fibrogenesis. <i>Antioxidants</i> , 2022, 11, 1278.	2.2	8
51	Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block. <i>Hepatology International</i> , 2013, 7, 299-305.	1.9	4
52	Hepatic Angiogenesis and Fibrogenesis in the Progression of Chronic Liver Diseases. <i>Current Angiogenesis</i> , 2013, 2, 23-29.	0.1	3
53	Oxidative Stress and Liver Fibrogenesis. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2015, , 171-196.	0.4	2
54	In vivo reprogramming of hepatic myofibroblasts into hepatocytes attenuates liver fibrosis: back to the future?. <i>Stem Cell Investigation</i> , 2016, 3, 53-53.	1.3	1

#	ARTICLE	IF	CITATIONS
55	Hyperdynamic circulatory syndrome in a mouse model transgenic for SerpinB3. <i>Annals of Hepatology</i> , 2020, 19, 36-43.	0.6	1